Cantor Fitzgerald initiated coverage of CytomX Therapeutics (CTMX) with an Overweight rating and $6 price target
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTMX:
- CytomX Therapeutics assumed with an Overweight at Barclays
- CytomX Therapeutics initiated with an Overweight at Barclays
- Barclays sees ‘significant potential’ in CytomX’s CX-2051 despite safety event
- CytomX trial ongoing despite grade five event, says Oppenheimer
- CytomX Therapeutics Updates on CX-2051 Phase 1 Study